Plerixafor

Generic Name
Plerixafor
Brand Names
Mozobil, Plerixafor Accord
Drug Type
Small Molecule
Chemical Formula
C28H54N8
CAS Number
110078-46-1
Unique Ingredient Identifier
S915P5499N
Background

Plerixafor is a small-molecule inhibitor of C-X-C chemokine receptor type 4 (CXCR4) that acts as a hematopoietic stem cell mobilizer. It is used to stimulate the release of stem cells from the bone marrow into the blood in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma to stimulate their immune system. These stem cells are then collected and...

Indication

Plerixafor is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma or multiple myeloma.

Associated Conditions
-
Associated Therapies
Mobilization of hematopoietic stem cells
Clinical Trials
Related News

Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

First Posted Date
2015-10-07
Last Posted Date
2024-11-05
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
59
Registration Number
NCT02570542
Locations
🇺🇸

Memorial Sloan Kettering Commack (Consent and Follow-up Only), Commack, New York, United States

🇺🇸

Memorial Sloan Kettering Westchester, Harrison, New York, United States

🇺🇸

Columbia University, New York, New York, United States

and more 11 locations

Quantitating the Impact of Plerixafor

First Posted Date
2015-08-13
Last Posted Date
2020-06-30
Lead Sponsor
E. Steve Woodle
Target Recruit Count
12
Registration Number
NCT02522572
Locations
🇺🇸

The Christ Hospital, Cincinnati, Ohio, United States

🇺🇸

University of Cincinnati, Cincinnati, Ohio, United States

HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection

First Posted Date
2015-01-22
Last Posted Date
2018-11-20
Lead Sponsor
Fred Hutchinson Cancer Center
Registration Number
NCT02343666
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome

First Posted Date
2014-09-04
Last Posted Date
2023-04-07
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
20
Registration Number
NCT02231879
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell Patients

First Posted Date
2014-08-08
Last Posted Date
2017-12-21
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
3
Registration Number
NCT02212535
Locations
🇫🇷

Hôpital Necker - Enfants Malades, Paris, France

Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease

Phase 1
Active, not recruiting
Conditions
Sickle Cell Disease
Interventions
Drug: Plerixafor
First Posted Date
2014-07-17
Last Posted Date
2024-11-05
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
25
Registration Number
NCT02193191
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

🇺🇸

Weill Cornell Medical College, New York, New York, United States

To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers

First Posted Date
2014-07-02
Last Posted Date
2019-07-23
Lead Sponsor
CCTU- Cancer Theme
Target Recruit Count
26
Registration Number
NCT02179970
Locations
🇬🇧

Addenbrookes Hospital, Cambridge, United Kingdom

Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma

First Posted Date
2014-03-27
Last Posted Date
2017-07-18
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
100
Registration Number
NCT02098109
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

First Posted Date
2013-12-19
Last Posted Date
2024-12-19
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
40
Registration Number
NCT02015013
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Stem Cell Harvesting Using GCSF Plus Plerxiafor, in First -Line, for Heavily Pre- Treated Pediatric Oncology Patients.

First Posted Date
2013-12-10
Last Posted Date
2013-12-10
Lead Sponsor
Tel-Aviv Sourasky Medical Center
Target Recruit Count
30
Registration Number
NCT02006225
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy